Interstitial lung disease in elderly

Дворецкий, Л. И.

doi:10.18093/0869-0189-2014-0-4-91-99

Cited by 2 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Недавно frailty определена как фактор риска неблагоприятных исходов не только у пожилых пациентов с патологией легких, но и у относительно молодых больных [4,5,18]. [19,20].…”

Section: современное представление о синдроме старческой астении (Fra...unclassified

Frailty syndrome in patients with respiratory diseases

Баздырев

Gofman

Barbarash

2022

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Respiratory diseases such as asthma and chronic obstructive pulmonary disease are especially prevalent in elderly people and have become a significant problem for healthcare due to ageing of population. Frailty syndrome (FS) is a geriatric syndrome characterized by an age-associated declines in physiologic reserve and functions of multiple systems, including respiratory system. This syndrome leads to increased vulnerability of the elderly.The aim of the study is to review the available data on modern understanding of FS, pathophysiological changes in the respiratory system associated with aging, the prevalence of FS, and its potential underlying mechanisms in elderly patients with respiratory diseases.Conclusion. FS is strongly associated with respiratory diseases. On one hand, these pathophysiological processes are inherent in elderly patients. On the other hand, the condition itself causes additional changes that enhance the aging process. Undoubtedly, their association and the influence of FS on the course and outcomes of the respiratory disease should be studied to improve the prognosis of elderly patients. Early recognition of FS in patients with respiratory diseases will help prevent or delay decline in physiologic reserve and functions of multiple systems and lower the disability and mortality rates. Comprehensive assessment of “frail” patients can assist in developing a better risk stratification and provide a personalized approach to managing these risks, as well as improve the patient outcomes.

show abstract

Section: современное представление о синдроме старческой астении (Fra...unclassified

Frailty syndrome in patients with respiratory diseases

Баздырев

Gofman

Barbarash

2022

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

show abstract

Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19

Chernyavskaya

Осипов

2021

Medicinskij sovet

View full text Add to dashboard Cite

One of the most likely and serious complications of the novel coronavirus infection (COVID-19) is pneumofibrosis, which can negatively affect the duration and quality of life of patients who have suffered from this disease. The appearance of fibrotic changes in COVID-19 is due to a number of pathological processes that occur in the lungs after the pathogen, the SARS- CoV-2 virus, enters there. First of all, an inflammatory response is triggered, which is mediated by macrophages and granulocytes, due to which the synthesis of pro-inflammatory cytokines, incl. IL-1, TNF, which are potent inducers of hyaluronic acid synthetase. There is a decrease in the content of fibrinolysis activators in the pulmonary endothelium, which contributes to the accumulation of fibrin in the vessels of the lungs. Fibrin can escape into the interstitial space and cause the formation of sclerosing alveolitis. The increasing defeat of pneumocytes favors the release of fibrin into the lumen of the alveoli, which causes the formation of hyaline membranes. The regulation of the fibrotic process involves immunocompetent cells, primarily CD4 + T-lymphocytes, which are capable of producing cytokines, chemokines and growth factors, and these, in turn, stimulate the proliferation and differentiation of fibroblasts, as well as their production of collagen. The more severe forms of infectious process can lead to the greater risk of developing fibrotic changes. Risk factors are a large area of lung damage, the use of artificial pulmonary ventilation, ARDS, fibrosis in anamnesis. An additional role in the pathomorphogenesis of pneumofibrosis is played by smoking, external inhalation effects (inhalation of organic and inorganic dust), gastroesophageal reflux, type II diabetes mellitus, genetic factors (familial idiopathic pulmonary fibrosis). The pathogenetic features of COVID-19 require administration of anti-fibrotic treatment. Bovhyaluronidazum azoximerum, a drug that is a conjugate of the proteolytic enzyme hyaluronidase, is considered as an antifibrotic agent. The treatment regimens with this drug recommended in the period of convalescence for patients who have undergone COVID-19 are given.

show abstract

Interstitial lung disease in elderly

Cited by 2 publications

References 59 publications

Frailty syndrome in patients with respiratory diseases

Frailty syndrome in patients with respiratory diseases

Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19

Contact Info

Product

Resources

About